following an abbreviated submission:
budesonide (Cortiment®) is accepted for use within NHSScotland.
Indication under review: Induction of remission in patients with active microscopic colitis.
Cortiment® offers a prolonged release formulation of budesonide for this indication. Other oral budesonide formulations are available at lower cost.
Download detailed advice717KB (PDF)
- Medicine name:
- budesonide (Cortiment)
- SMC ID:
Induction of remission in patients with active microscopic colitis (MC)
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Date advice published
- 17 January 2022